Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 13/20 | 0.38 |
| ▸ | SLC5A1 | P13866 | 10/20 | 0.38 |
| ▸ | HRH1 | P35367 | 5/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6510862 | 0.92 | SLC5A2 (0.43) | SLC5A2SLC5A1HRH1 | |
| SCHEMBL9789419 | 0.77 | — | — | |
| SCHEMBL27970168 | 0.72 | TSHR (0.33) | — | |
| SCHEMBL6415287 | 0.72 | SLC5A2 (0.41) | SLC5A2SLC5A1 | |
| SCHEMBL18259481 | 0.72 | — | — | |
| SCHEMBL27863829 | 0.71 | ALDH1A1 (0.35) | — | |
| SCHEMBL9235203 | 0.71 | SLC1A3 (0.32) | CYP2D6 | |
| SCHEMBL5974236 | 0.70 | SLC5A2 (0.42) | SLC5A2 | |
| SCHEMBL1267322 | 0.70 | SLC5A1 (0.32) | SLC5A2SLC5A1 | |
| SCHEMBL9093991 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050080022-A1 | Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives | KISSEI PHARMACEUTICAL CO., LTD. | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080022-A1 | Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885SLC5A1 2/4885HRH1 3860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.